Hamid Moradi

picture of Hamid  Moradi

Associate Director of Nephrology Fellowship Program, Medicine
School of Medicine

Associate Clinical Professor, Division of Nephrology, Hypertension & Kidney Transplantation, Medicine
School of Medicine


M.D., Oregon Health and Sciences University
B.S., University of California, Los Angeles, 1998, Cell, Molecular and Developmental Biology

Phone: (714) 456-5142
Fax: (714) 456-6034
Email: hmoradi@uci.edu

University of California, Irvine
333 City Boulevard West
Suite 400
Mail Code: 4088
Orange, CA 92868
Research Interests
High Density Lipoprotein, Endocannabinoids, End stage renal disease, Dialysis, Lipid metabolism
Academic Distinctions
-Orange County Medical Association Physician of Excellence 2015
-Member of the Dialysis Advisory Group (DAG) ASN 2015-2018
-Southern California Rising Stars Super Doctors 2014
-Marquis Who's Who® 2014
-Fellow of American Society of Nephrology 2012
-Fellow of American College of Physicians 2013
-Best Abstract annual meeting International Society of Blood Purification 2010
-First place winner – Scientific poster at the NKF-Kaiser Permanente Annual Meeting 2009 (Anaheim)
-Second place winner in basic science research. Young Investigator forum 2009.
-AFMR Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2009
-Carmel Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2008
-Endocrinology Scholar Award, Western American Federation for Medical Research (AFMR) meeting 2006
-Recipient of Alpha Omega Alpha (medical honor society) summer research fellowship OHSU 2000
-B.S. Suma Cum Laude with departmental honors UCLA 1997
Appointments
Staff Physician- Long Beach VA Healthcare System
Principal Investigator- Long Beach VA Healthcare System
Available Technologies
Publications
1. Klein, K., Reiter, R., Redula, J., Moradi, H., Zhu, X., Brothman, A., Lamb, D., Marcelli, M., Belldegrun, A., Witte, O., Sawyers, C. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. 1997. Nat Med. Apr; 3: 402-8.

2. Moradi, H., Kwok, V., Vaziri, ND. Effect of chronic renal failure on arginase and argininosuccinate synthetase expression. Am J Nephrol. 2006; 26: 310-8.

3. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009; 153: 77-85.

4. Pahl, M., Ni, Z., Sepassi, L., Moradi, H.,Vaziri ND. Plasma Phospholipid Transfer Protein, Cholesteryl Ester Transfer Protein and Lecithin: Cholesterol Acyltransferase In End-Stage Renal Disease (ESRD). Nephrol Dial Transplant. 2009; 24: 2541-6.

5. Moradi H., Yuan J., Norris K., Vaziri ND. Reverse cholesterol transport pathway in experimental renal failure. Am J Nephrol. 2009 24; 30:147-154.

6. Kim, H.J., Moradi, H., Yuan, J., Vaziri, ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009; 296: F1297-306.

7. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009; 76: 437-44.

8. Moradi, H., Ganji, S., Kamanna, V., Pahl, M.,Vaziri, ND. Antioxidant therapy does not improve inflammation or antioxidant activity in end-stage renal disease. Clin Nephrol. 2010; 74: 273-81.

9. Vaziri ND, Kim HJ, Moradi H, Farmand F, Navab K, Navab M, Hama S, Fogelman AM, Quiroz Y, Rodriguez-Iturbe B.. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrol Dial Transplant. 2010; 25: 3525-34.

10. Vaziri, ND., Moradi, H., Pahl, M., Gollapudi, P., Barton, C.H., Navab, M. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011; 103: 524-33.

11. Bukhari, FJ, Moradi, H., Kim, HJ., Vaziri, ND., Said, HM. Effect of chronic kidney disease on the expression of Thiamin and Folic acid transporters. Nephrol Dial Transplant. 2011; 26: 2137-44.

12. Vaziri ND, Gollapudi P, Han S, Farahmand G, Yuan J, Rahimi A, Moradi H. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor. Nephrol Dial Transplant. 2011; 26: 3118-23.

13. Vaziri, ND, Goshtasbi, N, Yuan, J, Jellbauer, S, Moradi, H, Raffatellu M, Kalantar-Zadeh K. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol. 2012; 36: 438-43.

14. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res. 2013 ;161:477-85

15. Han, SY, Vaziri, ND, Gollapudi, P, Kwok, V, Moradi, H. Hepatic fatty acid and cholesterol metabolism in nehprotic syndrome. Am J Transl Res. 2013; 5: 246-53.

16. Subramanian VS, Nabokina SM, Patton JR, Marchant JS, Moradi H, Said HM. Glyoxalate reductase/hydroxypyruvate reductase interacts with the sodium-dependent vitamin C transporter-1 to regulate cellular vitamin C homeostasis. Am J Physiol Gastrointest Liver Physiol. 2013; 304: G1079-86.

17. Lertdumrongluk P, Rhee CM, Park J, Lau WL, Moradi H, Jing J, Molnar MZ, Brunelli SM, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K. Association of Serum Phosphorus Concentration With Mortality in Elderly and Nonelderly Hemodialysis Patients. J Ren Nutr. 2013; 23:411-21.

18. Yazdi PG*, Moradi H*, Yang JY, Wang PH, Vaziri ND. Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med. 2013; 6: 532-9. (Co First-Author)

19. Hatamizadeh P, Ravel V, Lukowsky LR, Molnar MZ, Moradi H, Harley K, Pahl M, Kovesdy CP, Kalantar-Zadeh K. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant. 2013; 28: 2889-98.

20. Rhee CM, Lertdumrongluk P, Streja E, Park J, Moradi H, Lau WL, Norris KC, Nissenson AR, Amin AN, Kovesdy CP, Kalantar-Zadeh K. Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities. Am J Nephrol. 2014;39:183-94.

21. Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014; 29:1554-62.

22. Li L, Fisher M, Lau WL, Moradi H, Cheung A, Thai G, Handwerker J, Kalantar-Zadeh K. Cerebral microbleeds and cognitive decline in a hemodialysis patient: Case report and review of literature. Hemodial Int. 2015; 19: E1-7.

23. Kalantar-Zadeh K, Tortorici AR, Chen JL, Kamgar M, Lau WL, Moradi H, Rhee CM, Streja E, Kovesdy CP. Dietary Restrictions in Dialysis Patients: Is There Anything Left to Eat? Semin Dial. 2015; 28: 159-68.

24. Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, Gillen D, Pahl MV, Vaziri ND, Kalantar-Zadeh K. Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. Am J Nephrol. 2015; 41: 284-95.

25. Rhee CM, Nguyen DV, Moradi H, Brunelli SM, Dukkipati R, Jing J, Nakata T, Kovesdy CP, Brent GA, Kalantar-Zadeh K. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2015; 66: 313-21.

26. Ahmadi SF, Streja E, Zahmatkesh G, Streja D, Kashyap M, Moradi H, Molnar MZ, Reddy U, Amin AN, Kovesdy CP, Kalantar-Zadeh K. Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. J Am Med Dir Assoc. 2015; 16: 933-9.

27. Ravel V, Streja E, Molnar MZ, Rezakhani S, Soohoo M, Kovesdy CP, Kalantar-Zadeh K, Moradi H. Association of aspartate aminotransferase with mortality in hemodialysis patients. Nephrol Dial Transplant. 2016; 31: 814-22.

28. Doshi M, Streja E, Rhee CM, Park J, Ravel VA, Soohoo M, Moradi H, Lau WL, Mehrotra R, Kuttykrishnan S, Kovesdy CP, Kalantar-Zadeh K, Chen JL. Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial Transplant. 2016; 31: 1310-9.

29. Vashistha T, Streja E, Molnar MZ, Rhee CM, Moradi H, Soohoo M, Kovesdy CP, Kalantar-Zadeh K. Red Cell Distribution Width and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2016; 68: 110-21.

30. Moradi H, Oveisi F, Khanifar E, Moreno-Sanz G, Vaziri ND, Piomelli D. Increased renal 2-arachidonoylglycerol levels are associated with improved renal function in a mouse model of acute kidney injury. Cannabis and Cannabinoid Res. 2016; 1: 218-228.

31. Soohoo M, Ahmadi SF, Qader H, Streja E, Obi Y, Moradi H, Rhee CM, Kim TH, Kovesdy CP, Kalantar-Zadeh K. Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients. Nephrol Dial Transplant. 2017 Jun 1;32(6):1024-1032.

32. Kalantar-Zadeh K, Crowley ST, Beddhu S, Chen JLT, Daugirdas JT, Goldfarb DS, Jin A, Kovesdy CP, Leehey DJ, Moradi H, Navaneethan SD, Norris KC, Obi Y, O'Hare A, Shafi T, Streja E, Unruh ML, Vachharajani TJ, Weisbord S, Rhee CM. Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. Semin Dial. 2017 May;30(3):251-261.

33. Perl J, Dember LM, Bargman JM, Browne T, Charytan DM, Flythe JE, Hickson LJ, Hung AM, Jadoul M, Lee TC, Meyer KB, Moradi H, Shafi T, Teitelbaum I, Wong LP, Chan CT; American Society of Nephrology Dialysis Advisory Group. The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics. Clin J Am Soc Nephrol. 2017 May 8;12(5):839-847.

34. Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy C, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H. Association of serum triglyceride to high-density lipoprotein cholesterol ratio with outcomes in incident hemodialysis patients. CJASN. 2017 Apr 3;12(4):591-602.

35. Subramanian VS, Sabui S, Moradi H, Marchant JS, Said HM. Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanism(s). Biochim Biophys Acta. 2017 Oct 10. pii: S0005-2736(17)30320-6. doi: 10.1016/j.bbamem.2017.

36. Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, Moradi H.
LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.
37. Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H. LCZ696 (Sacubitril/valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis and Vasculopathy in a Rat Model of Chronic Kidney Disease. J Card Fail. 2018 Jan 8. pii: S1071-9164(18)30002-2.

38. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, Balkrishnan R, Dietrich X, Eckard A, Eggers PW, Gaipov A, Gillen D, Gipson D, Hailpern SM, Hall YN, Han Y, He K, Herman W, Heung M, Hirth RA, Hutton D, Jacobsen SJ, Jin Y, Kalantar-Zadeh K, Kapke A, Kovesdy CP, Lavallee D, Leslie J, McCullough K, Modi Z, Molnar MZ, Montez-Rath M, Moradi H, Morgenstern H, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O'Hare AM, Obi Y, Park C, Pearson J, Pisoni R, Potukuchi PK, Rao P, Repeck K, Rhee CM, Schrager J, Schaubel DE, Selewski DT, Shaw SF, Shi JM, Shieu M, Sim JJ, Soohoo M, Steffick D, Streja E, Sumida K, Tamura MK, Tilea A, Tong L, Wang D, Wang M, Woodside KJ, Xin X, Yin M, You AS, Zhou H, Shahinian V. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2018 Mar;71(3S1):A7. doi: 10.1053/j.ajkd.2018.01.002.

39. Chang TI, Streja E, Soohoo M, Ko GJ, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H. Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. J Clin Lipidol. 2018; 12 :488-497.

40. Kleine CE, Soohoo M, Ranasinghe ON, Park C, Marroquin MV, Obi Y, Rhee CM, Moradi H, Kovesdy CP, Kalantar-Zadeh K, Streja E. Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes. Am J Nephrol. 2018; 47: 333-342.

41. Han Z, Xiao Z, Kalantar-Zadeh K, Moradi H, Shafi T, Waikar SS, Quarles LD, Yu Z, Tin A, Coresh J, Kovesdy CP. Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. Diagnostics (Basel). 2018 Oct 8;8(4).

42. Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H. Inverse Association between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Incident Hemodialysis Patients. J Am Heart Assoc. 2018 Jun 9;7(12).

43. Streja E, Gosmanova EO, Molnar MZ, Soohoo M, Moradi H, Potukuchi PK, Kalantar-Zadeh K, Kovesdy CP. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Netw Open. 2018 Oct 5;1(6):e182311.

44. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, Bhave N, Dietrich X, Ding Z, Eggers PW, Gaipov A, Gillen D, Gipson D, Gu H, Guro P, Haggerty D, Han Y, He K, Herman W, Heung M, Hirth RA, Hsiung JT, Hutton D, Inoue A, Jacobsen SJ, Jin Y, Kalantar-Zadeh K, Kapke A, Kleine CE, Kovesdy CP, Krueter W, Kurtz V, Li Y, Liu S, Marroquin MV, McCullough K, Molnar MZ, Modi Z, Montez-Rath M, Moradi H, Morgenstern H, Mukhopadhyay P, Nallamothu B, Nguyen DV, Norris KC, O'Hare AM, Obi Y, Park C, Pearson J, Pisoni R, Potukuchi PK, Repeck K, Rhee CM, Schaubel DE, Schrager J, Selewski DT, Shamraj R, Shaw SF, Shi JM, Shieu M, Sim JJ, Soohoo M, Steffick D, Streja E, Sumida K, Kurella Tamura M, Tilea A, Turf M, Wang D, Weng W, Woodside KJ, Wyncott A, Xiang J, Xin X, Yin M, You AS, Zhang X, Zhou H, Shahinian V. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019; 73: A7-A8.

45. Hsiung JT, Kleine CE, Naderi N, Park C, Soohoo M, Moradi H, Rhee CM, Obi Y, Kopple JD, Kovesdy CP, Kalantar-Zadeh K, Streja E. Association of Pre-End-Stage Renal Disease Serum Albumin With Post-End-Stage Renal Disease Outcomes Among Patients Transitioning to Dialysis. J Ren Nutr. 2019; 29: 310-321.

46. Lertdumrongluk P, Streja E, Rhee CM, Moradi H, Chang Y, Reddy U, Tantisattamo E, Kalantar-Zadeh K, Kopp JB. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. Cardiorenal Med. 2019; 9: 212-221.

47. Suematsu Y, Goto M, Park C, Nunes ACF, Jing W, Streja E, Rhee CM, Cruz S, Kashyap ML, Vaziri ND, Narayanaswami V, Kalantar-Zadeh K, Moradi H. Association of Serum Paraoxonase/Arylesterase Activity with All-Cause Mortality in Maintenance Hemodialysis Patients. J Clin Endocrinol Metab. 2019; 104: 4848-4856

48. Soohoo M, Moradi H, Obi Y, Rhee CM, Gosmanova EO, Molnar MZ, Kashyap ML, Gillen DL, Kovesdy CP, Kalantar-Zadeh K, Streja E. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc. 2019 8(6):e011869.

49. Lertdumrongluk P, Streja E, Rhee CM, Moradi H, Chang Y, Reddy U, Tantisattamo E, Kalantar-Zadeh K, Kopp JB. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. Cardiorenal Med. 2019; 9: 212-221.

50. Soohoo M, Moradi H, Obi Y, Kovesdy CP, Kalantar-Zadeh K, Streja E. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol. 2019 Aug 8. pii: S1933-2874(19)30265-X.

51. Moradi H, Park C, Igarashi M, Streja E, Argueta DA, Soohoo M, Daglian J, You AS, Rhee CM, Kashyap ML, DiPatrizio NV, Vaziri ND, Kalantar-Zadeh K, Piomelli D. Serum Endocannabinoid Levels in Patients with End-Stage Renal Disease. Journal of the Endocrine Society. 2019; 3:1869-1880.

Guest Editor (Special Edition Seminars in Nephrology 2018)
1. Moradi H, Kalantar-Zadeh K. Introduction: Precision Medicine in End-Stage Kidney Disease and Personalized Renal Replacement Therapy: Challenges and Unmet Need. Semin Nephrol. 2018 Jul;38(4):315-316.

Editorials
1. Moradi H, Wang P. Renoprotective mechanisms of ischemic postconditioning in ischemia–reperfusion injury: improved mitochondrial function and integrity. Nephrol Dial Transplant. 2013; 28: 2667-9.

2. Dual role of circulating angiopoietin-like 4 (ANGPTL4) in promoting hypertriglyceridemia and lowering proteinuria in nephrotic syndrome. Vaziri ND, Moradi H. Am J Kidney Dis. 2014 Oct;64(4):495-8.

3. Moradi H., Said HM. Functional thiamine deficiency in end stage renal disease: malnutrition in spite of ample nutrients. Kid Int. 2016; 90: 252-4.

4. Moradi H., Vaziri ND. Resveratrol in polycystic kidney disease: a case of cautious optimism. Nephrol Dial Transplant. 2016; 31: 1755-1758.

5. Moradi H., Streja E., Kalantar-Zadeh K. Serum High Density Lipoprotein cholesterol level and Risk of Death: Let’s avoid the extremes. Journal of Thoracic Disease. 2017; 9: 4849-4852.

6. Chang Y, Moradi H, Kalantar-Zadeh K. Emerging paradigms of treating diabetic nephropathy. Lancet Diabetes Endocrinol. 2018; 6: 912-913.

Reviews
1. Vaziri, ND, Moradi, H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006; 10(1):1-7.

2. Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K. Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword. J Ren Nutr. 2013; 23: 203-6.

3. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013; 38: 136-48.

4. Esmaeili A, Sharifzadeh M, Naghshineh S, Moradi H, Vaziri ND. Role of HDL, ApoA-I, and related peptides in protection against atherosclerosis. Current Topics in Peptide & Protein Research. 2014; 15: 79 – 89.

5. Streja E, Kovesdy CP, Streja DA, Moradi H, Kalantar-Zadeh K, Kashyap ML. Niacin and Progression of CKD. Am J Kidney Dis. 2015; 65: 785-98.

6. Chang TI, Streja E, Moradi H. Could high-density lipoprotein cholesterol predict increased cardiovascular risk? Curr Opin Endocrinol Diabetes Obes. 2017; 24:140-147.

7. Park F, Potukuchi PK, Moradi H, Kovesdy CP. Cannabinoids and the Kidney: Effects in Health and Disease. Am J Physiol Renal Physiol. 2017; 313: F1124-F1132.

8. Moradi H, Vaziri ND. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed). 2018; 23: 146-161.

9. Moradi H, Streja E, Vaziri ND. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients? Semin Dial. 2018; 31: 398-405.

10. Streja E, Streja DA, Soohoo M, Kleine CE, Hsiung JT, Park C, Moradi H. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. Semin Nephrol. 2018 Jul;38(4):369-382.

11. Naderi N, Kleine CE, Park C, Hsiung JT, Soohoo M, Tantisattamo E, Streja E, Kalantar-Zadeh K, Moradi H. Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. Prog Cardiovasc Dis. 2018; 61(2):168-181.

12. Kleine CE, Moradi H, Streja E, Kalantar-Zadeh K. Racial and Ethnic Disparities in the Obesity Paradox. Am J Kidney Dis. 2018; 72: S26-S32.

13. Chua JT, Argueta DA, DiPatrizio NV, Kovesdy CP, Vaziri ND, Kalantar-Zadeh K, Moradi H. Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease. Cannabis Cannabinoid Res. 2019 Mar 13;4(1):10-20.
Grants
1 IK CX 001043-01A2 VA ORD Career Development Award
2009-2013 NIH F32-DK-082130 NRSA Post-Doctoral Fellowship 2007-2008
Professional Society
American Society of Nephrology
Last updated
01/13/2020